What is new in the assessment of etiopathogenetic modalities of cardiorenal diseases?

7th International Congress of Cardionephrology KARNEF (2025) [pp. 9-12]

AUTHOR(S) / АУТОР(И): Rodolfo Fernando Rivera

Download Full Pdf   

DOI: 10.46793/KARNEF25.009R

ABSTRACT / САЖЕТАК:

The pathophysiological framework of cardiorenal diseases has undergone a significant conceptual shift. Once regarded primarily as a hemodynamic interplay between the heart and kidneys, cardiorenal syndromes are now interpreted through the lens of complex multisystem dysfunction. Emerging evidence highlights the pivotal role of systemic inflammation, oxidative stress, gut dysbiosis, and neurohormonal imbalance in mediating this interplay. Novel biomarkers and high-throughput technologies, including multi-omics and artificial intelligence, offer unprecedented insights into early and overlapping mechanisms of injury. This evolving landscape challenges traditional assessment models and opens the way for a new integrative, personalized approach to diagnosis and management.

KEYWORDS / КЉУЧНЕ РЕЧИ:

cardiorenal diseases, multisystem dysfunction, multi-omics, artificial intelligence, personalized approach

REFERENCES / ЛИТЕРАТУРА:

  • Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. López‐Sanz, D., et al. Pathophysiology of cardiorenal syndrome: Molecular mechanisms and clinical insights. Heart J., 2020, 41(22), 2191–2201.
  • Yap, L. M., et al. The role of inflammation and oxidative stress in cardiorenal syndrome. Heart Failure Reviews, 2019, 24(2), 223-234.
  • Mullens, W., et al. Cardiorenal syndrome: Pathophysiology, diagnosis, and management. Rev. Nephrol., 2018, 14(6), 363–376.
  • Nicolini, F., et al. The gut microbiota and its role in systemic inflammation: Implications for cardiovascular and renal diseases. Cardiovasc. Med., 2021, 8, 639597.
  • Rojas‐Morales, P., et al. Epigenetics and kidney disease: An emerging field in renal pathophysiology. J. Physiol. – Renal Physiology, 2018, 314(4), F614–F625.
  • Katz, R., et al. Early identification of kidney dysfunction in patients with heart failure. Current Opinion in Cardiology, 2017, 32(3), 305-311.
  • Packer, M., et al. New insights into the neurohormonal mechanisms of cardiorenal syndrome: Implications for therapeutic strategies. Am. Coll. Card., 2019, 74(18), 2339-2348.
  • Laffin, L. J., et al. The role of epigenetics in cardiorenal syndrome: From mechanisms to thera-peutic opportunities. Cardiovasc. Transl. Res., 2020, 13(5), 673–680.
  • Bär, T., et al. Emerging insights into the complex mechanisms of cardiorenal syndrome: Current perspectives and future directions. Dial. Transplant., 2021, 36(4), 577-586.
  • Bansal, N., et al. Cardiorenal syndrome and the gut microbiome: Unraveling the connection. Am. Soc. Nephrol., 2019, 30 (10), 1827-1835.
  • Vasilenko, R., et al. Integrating -omics technologies in the study of cardiorenal syndrome: Current state and future perspectives. Frontiers in Molecular Biosciences, 2020, 7, 87.
  • Chrysafides, J. J., et al. The role of systemic inflammation in cardiorenal syndrome: A review of patho-physiology and clinical implications. Ren. Hep. Disord., 2022, 1(2), 78-84.
  • Berg, R. L., et al. Clinical biomarkers in cardiorenal syndrome: Translational findings in the era of precision medicine. Clin. Med., 2019, 8(12), 2067.